C4 Therapeutics (CCCC) Short Interest Ratio & Short Volume $3.01 +0.02 (+0.67%) Closing price 04:00 PM EasternExtended Trading$3.03 +0.02 (+0.63%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends C4 Therapeutics Short Interest DataC4 Therapeutics (CCCC) has a short interest of 7.40 million shares. This marks a -20.26% decrease in short interest from the previous month. The short interest ratio (days to cover) is 4.4, indicating that it would take 4.4 days of the average trading volume of 1.86 million shares to cover all short positions.Current Short Interest7,400,000 sharesPrevious Short Interest9,280,000 sharesChange Vs. Previous Month-20.26%Dollar Volume Sold Short$25.68 millionShort Interest Ratio4.4 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares70,589,000 sharesPercentage of Shares Shorted10.48%Today's Trading Volume1,734,444 sharesAverage Trading Volume1,857,339 sharesToday's Volume Vs. Average93% Short Selling C4 Therapeutics? Sign up to receive the latest short interest report for C4 Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCCCC Short Interest Over TimeCCCC Days to Cover Over TimeCCCC Percentage of Float Shorted Over Time C4 Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/20257,400,000 shares $25.68 million -20.3%N/A4.4 $3.47 1/15/20259,280,000 shares $37.49 million +7.9%N/A6 $4.04 12/31/20248,600,000 shares $30.96 million -3.0%N/A6.4 $3.60 12/15/20248,870,000 shares $38.85 million +11.0%N/A7.3 $4.38 11/30/20247,990,000 shares $36.35 million +8.0%N/A7.3 $4.55 11/15/20247,400,000 shares $31.89 million +26.5%N/A7.3 $4.31 10/31/20245,850,000 shares $31.18 million -12.0%N/A6 $5.33 10/15/20246,650,000 shares $41.90 million -39.6%N/A6.7 $6.30 9/30/202411,010,000 shares $62.76 million -7.6%N/A9 $5.70 9/15/202411,920,000 shares $76.76 million +2.5%N/A8.1 $6.44 Get the Latest News and Ratings for CCCC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202411,630,000 shares $73.50 million +10.8%N/A7.4 $6.32 8/15/202410,500,000 shares $61.53 million +0.3%N/A6.6 $5.86 7/31/202410,470,000 shares $70.15 million -10.0%N/A6.3 $6.70 7/15/202411,630,000 shares $75.48 million +32.0%N/A7 $6.49 6/30/20248,810,000 shares $40.70 million -39.4%N/A5.7 $4.62 6/15/202414,540,000 shares $63.69 million +9.7%N/A10.2 $4.38 5/31/202413,260,000 shares $66.30 million +16.9%N/A8.4 $5.00 5/15/202411,340,000 shares $69.29 million +11.8%N/A5.9 $6.11 4/30/202410,140,000 shares $63.88 million +6.1%N/A4.5 $6.30 4/15/20249,560,000 shares $65.58 million +4.5%N/A3.7 $6.86 3/31/20249,150,000 shares $74.76 million +73.0%N/A2.4 $8.17 3/15/20245,290,000 shares $47.24 million +78.1%N/A1.1 $8.93 2/29/20242,970,000 shares $32.61 million -6.6%N/A0.2 $10.98 2/15/20243,180,000 shares $25.12 million -5.1%N/A0.2 $7.90 1/31/20243,350,000 shares $20.70 million -39.6%8.7%0.2 $6.18 1/15/20245,550,000 shares $37.74 million +22.3%14.5%0.4 $6.80 12/31/20234,540,000 shares $25.65 million -44.0%10.8%0.3 $5.65 12/15/20238,100,000 shares $40.10 million +330.9%19.3%0.7 $4.95 11/30/20231,880,000 shares $3.06 million -3.6%4.5%3.4 $1.63 11/15/20231,950,000 shares $3.51 million +2.1%4.7%4.1 $1.80 10/31/20231,910,000 shares $2.85 million +4.4%4.6%3.9 $1.49 10/15/20231,830,000 shares $3.64 million -19.0%4.6%3.8 $1.99 9/30/20232,260,000 shares $4.20 million -5.0%5.6%5.2 $1.86 9/15/20232,380,000 shares $5.31 million +14.4%5.9%2.4 $2.23 8/31/20232,080,000 shares $6.03 million +9.5%5.2%1.9 $2.90 8/15/20231,900,000 shares $6.42 million -10.0%4.7%1.6 $3.38 7/31/20232,110,000 shares $8.21 million -5.8%5.3%1.7 $3.89 7/15/20232,240,000 shares $7.50 million -8.9%5.6%1.8 $3.35 6/30/20232,460,000 shares $6.77 million -26.4%6.1%2 $2.75 6/15/20233,340,000 shares $12.06 million +2.8%8.3%5.1 $3.61Market down? Do this now. (Ad)During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.Download your Free 2025 Gold Guide Now 5/31/20233,250,000 shares $11.02 million +12.1%8.1%5.4 $3.39 5/15/20232,900,000 shares $9.69 million +0.7%7.2%5.2 $3.34 4/30/20232,880,000 shares $8.70 million +1.8%7.0%5 $3.02 4/15/20232,830,000 shares $9.48 million +7.6%6.9%4.9 $3.35 3/31/20232,630,000 shares $8.26 million -9.9%6.5%4.5 $3.14 3/15/20232,920,000 shares $12.59 million -10.2%7.2%5.1 $4.31 2/28/20233,250,000 shares $17.13 million +0.9%8.0%6.3 $5.27 2/15/20233,220,000 shares $18.58 million -12.5%7.9%6.1 $5.77 1/31/20233,680,000 shares $28.67 million +2.8%9.0%7 $7.79 1/15/20233,580,000 shares $30.57 million +2.0%8.8%7.8 $8.54 12/30/20223,510,000 shares $20.71 million -3.6%8.6%7.8 $5.90 12/15/20223,640,000 shares $29.48 million +0.3%8.9%8 $8.10 11/30/20223,630,000 shares $31.11 million -8.1%8.9%7.5 $8.57 11/15/20223,950,000 shares $38.39 million -19.1%9.7%8.5 $9.72 10/31/20224,880,000 shares $46.95 million -1.2%11.9%11.4 $9.62 10/15/20224,940,000 shares $39.32 million -2.0%12.9%12.1 $7.96 9/30/20225,040,000 shares $44.20 million +11.0%13.2%11.9 $8.77 9/15/20224,540,000 shares $51.57 million -6.8%11.8%9.8 $11.36 8/31/20224,870,000 shares $49.09 million -5.1%12.7%9.9 $10.08 8/15/20225,130,000 shares $62.23 million -3.2%13.4%9.2 $12.13 7/31/20225,300,000 shares $51.09 million +1.5%13.9%8.2 $9.64 7/15/20225,220,000 shares $52.30 million +2.8%13.7%7.2 $10.02 6/30/20225,080,000 shares $38.30 million +20.7%13.3%4.7 $7.54 6/15/20224,210,000 shares $23.11 million -2.1%11.0%3.7 $5.49 5/31/20224,300,000 shares $31.22 million +10.3%11.3%4.2 $7.26 5/15/20223,900,000 shares $27.89 million -23.7%10.2%3.9 $7.15 4/30/20225,110,000 shares $43.79 million -4.7%13.4%5.4 $8.57 4/15/20225,360,000 shares $47.97 million +4.7%14.0%5.8 $8.95 3/31/20225,120,000 shares $124.21 million +8.5%13.4%7.2 $24.26 3/15/20224,720,000 shares $101.48 million +29.7%12.4%9.8 $21.50 2/28/20223,640,000 shares $81.65 million +8.7%9.5%7.6 $22.43 2/15/20223,350,000 shares $80.03 million +23.2%8.8%7.7 $23.89 1/31/20222,720,000 shares $66.45 million -13.1%7.1%6.7 $24.43 1/15/20223,130,000 shares $86.20 million -1.6%8.1%9.5 $27.54 12/31/20213,180,000 shares $102.40 million +6.0%8.3%10.9 $32.20 12/15/20213,000,000 shares $91.50 million +8.3%7.8%11 $30.50 11/30/20212,770,000 shares $102.82 million +0.4%7.2%10.6 $37.12 11/15/20212,760,000 shares $115.09 million +2.2%7.2%10.3 $41.70 10/29/20212,700,000 shares $119.93 million +1.5%7.0%9.9 $44.42 10/15/20212,660,000 shares $116.75 million No Change6.9%8.7 $43.89 9/30/20212,660,000 shares $118.85 million +17.2%6.9%7.9 $44.68 9/15/20212,270,000 shares $110.75 million -6.2%5.9%5.7 $48.79 8/31/20212,420,000 shares $97.11 million -11.7%6.6%5.5 $40.13 8/13/20212,740,000 shares $107.82 million +3.4%7.4%6 $39.35 7/30/20212,650,000 shares $114.32 million No Change8.1%5.5 $43.14 7/15/20212,650,000 shares $98.90 million -5.0%8.1%5.8 $37.32 6/30/20212,790,000 shares $105.57 million +18.2%8.5%6 $37.84 6/15/20212,360,000 shares $88.88 million -3.7%7.2%5.5 $37.66 5/28/20212,450,000 shares $90.53 million -7.9%7.4%6.4 $36.95 5/14/20212,660,000 shares $90.60 million +1.9%8.0%7.7 $34.06Market down? Do this now. (Ad)During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.Download your Free 2025 Gold Guide Now 4/30/20212,610,000 shares $89.37 million -12.1%7.9%8.6 $34.24 4/15/20212,970,000 shares $98.54 million -19.1%9.0%10.3 $33.18 3/31/20213,670,000 shares $120.74 million +77.3%11.1%13.8 $32.90 3/15/20212,070,000 shares $92.40 million +6.7%6.4%8 $44.64 2/26/20211,940,000 shares $81.00 million +21.3%5.9%7.7 $41.75 2/12/20211,600,000 shares $72.86 million +3.9%4.8%5.5 $45.54 1/29/20211,540,000 shares $55.70 million -14.9%4.4%3.9 $36.17 1/15/20211,810,000 shares $68.73 million No Change5.2%3.8 $37.97 CCCC Short Interest - Frequently Asked Questions What is C4 Therapeutics' current short interest? Short interest is the volume of C4 Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 7,400,000 shares of CCCC short. Learn More on C4 Therapeutics' current short interest. What is a good short interest ratio for C4 Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CCCC shares currently have a short interest ratio of 4.0. Learn More on C4 Therapeutics's short interest ratio. Which institutional investors are shorting C4 Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of C4 Therapeutics: Group One Trading LLC, Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is C4 Therapeutics' short interest increasing or decreasing? C4 Therapeutics saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 7,400,000 shares, a decrease of 20.3% from the previous total of 9,280,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does C4 Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to C4 Therapeutics: ArriVent BioPharma, Inc. (22.15%), Cogent Biosciences, Inc. (9.17%), Oculis Holding AG (0.05%), Bicycle Therapeutics plc (6.23%), Ginkgo Bioworks Holdings, Inc. (22.61%), Immunome, Inc. (13.01%), Avadel Pharmaceuticals plc (10.95%), CureVac (3.89%), Avid Bioservices, Inc. (18.17%), Nuvation Bio Inc. (11.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short C4 Therapeutics stock? Short selling CCCC is an investing strategy that aims to generate trading profit from C4 Therapeutics as its price is falling. CCCC shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against C4 Therapeutics? A short squeeze for C4 Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CCCC, which in turn drives the price of the stock up even further. How often is C4 Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CCCC, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies AVBP Short Interest COGT Short Interest OCS Short Interest BCYC Short Interest DNA Short Interest IMNM Short Interest AVDL Short Interest CVAC Short Interest CDMO Short Interest NUVB Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CCCC) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CCCC Stock Alerts